epetraborole
Small moleculeexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT01015014)
Timeline
Indications
Mechanism of action
- Leucine--tRNA ligaseINHIBITOR
leuS inhibitor
- Leucine--tRNA ligaseINHIBITOR
Leucine--tRNA ligase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NC[C@H]1OB(O)c2c(OCCCO)cccc21- Mol. weight
- 237.06 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3549142 ↗
Also known as
- an3365
- an3365
- epetraborole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07301320 | Phase 2 | Jan 31, 2026 | AN2 Therapeutics, Inc, Oregon Health and Science University |
| NCT05995444 | Phase 1 | Jun 5, 2023 | AN2 Therapeutics, Inc |
| NCT05327803 | Phase 2/Phase 3 (Phase 3) | May 20, 2022 | AN2 Therapeutics, Inc |
| NCT05283746 | Phase 1 | Feb 21, 2022 | Advanced Pharma CR, LLC, AN2 Therapeutics, Inc, Nucleus Network Ltd, Orlando Clinical Research Center |
| NCT04892641 | Phase 1 | Jun 30, 2021 | AN2 Therapeutics, Inc, CMAX Clinical Research |
| NCT01015014 | Phase 1 | Nov 1, 2009 | Pfizer |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc | For profit | 5 | 4 | 3 | 2021 |
| Advanced Pharma CR, LLC | For profit | 1 | 0 | 1 | 2022 |
| CMAX Clinical Research | For profit | 1 | 0 | 1 | 2021 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2022 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Orlando Clinical Research Center | For profit | 1 | 0 | 1 | 2022 |
| Pfizer | For profit | 1 | 1 | 1 | 2009 |
7 organizations
Page 1 / 1